xAnts

Hims & Hers Health falls as FDA issues unfavorable compounded GLP-1 decision

Hims & Hers Health (NYSE:HIMS) is down 7% in early morning trading after the U.S. FDA determined that there is no shortage of Eli Lilly's (LLY) GLP-1 medication tirzepatide, the active ingredient in its weight loss and type 2 diabetes therapies Zepbo Read more